GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Shiller PE Ratio

Arbutus Biopharma (Arbutus Biopharma) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Shiller PE Ratio Historical Data

The historical data trend for Arbutus Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Shiller PE Ratio Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arbutus Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arbutus Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, Arbutus Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Shiller PE Ratio falls into.



Arbutus Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arbutus Biopharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Arbutus Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.1/129.4194*129.4194
=-0.100

Current CPI (Mar. 2024) = 129.4194.

Arbutus Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.280 100.560 -0.360
201409 -0.390 100.428 -0.503
201412 -0.270 99.070 -0.353
201503 -0.400 99.621 -0.520
201506 -0.270 100.684 -0.347
201509 -0.570 100.392 -0.735
201512 -0.100 99.792 -0.130
201603 -0.310 100.470 -0.399
201606 -2.470 101.688 -3.144
201609 -0.370 101.861 -0.470
201612 -4.090 101.863 -5.196
201703 -0.340 102.862 -0.428
201706 -0.330 103.349 -0.413
201709 -0.210 104.136 -0.261
201712 -0.670 104.011 -0.834
201803 -0.360 105.290 -0.443
201806 0.010 106.317 0.012
201809 -0.490 106.507 -0.595
201812 -0.370 105.998 -0.452
201903 -0.470 107.251 -0.567
201906 -0.460 108.070 -0.551
201909 -1.500 108.329 -1.792
201912 -0.460 108.420 -0.549
202003 -0.250 108.902 -0.297
202006 -0.250 108.767 -0.297
202009 -0.270 109.815 -0.318
202012 -0.230 109.897 -0.271
202103 -0.210 111.754 -0.243
202106 -0.230 114.631 -0.260
202109 -0.240 115.734 -0.268
202112 -0.150 117.630 -0.165
202203 -0.110 121.301 -0.117
202206 -0.100 125.017 -0.104
202209 -0.120 125.227 -0.124
202212 -0.140 125.222 -0.145
202303 -0.100 127.348 -0.102
202306 -0.100 128.729 -0.101
202309 -0.120 129.860 -0.120
202312 -0.120 129.419 -0.120
202403 -0.100 129.419 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (NAS:ABUS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arbutus Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma (Arbutus Biopharma) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Executives
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims officer: Chief Medical Officer 701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger officer: General Counsel and CCO 633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia officer: Chief Scientific Officer C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran director C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh officer: Chief Business Officer C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers director GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng director 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier director, officer: President and CEO C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard officer: Executive VP & General Counsel 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings officer: Chief Financial Officer C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio officer: Chief Development Officer C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8